AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00136591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Arm A: a 21-day cycle of 1.5 mg/m2 Velcade™ twice weekly for 2 weeks. Days 1, 4, 8, and 11 of a 21-day cycle
Study NCT00136591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Arm B: a 35-day cycle of 1.6 mg/m2 Velcade™once weekly for 4 weeks. Days 1, 8, 15, and 22 of a 35-day cycle. Subjects in this treatment arm will receive a total of 6 cycles of treatment, approximately 30 weeks.
Study NCT04503876 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Increasing PEEP setting
Description: End expiratory lung volume and lung aeration measurements will be conducted using electrical impedance tomography and nitrogen washin-washout method. Measurements will be conducted during the last minute of each step.
Study NCT04503876 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decreasing PEEP setting
Description: End expiratory lung volume and lung aeration measurements will be conducted using electrical impedance tomography and nitrogen washin-washout method. Measurements will be conducted during the last minute of each step.
Study NCT02076542 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education - Diabetes and Sports
Description: Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Sports was created. The module covers specific and detailed aspects of the topic sports such as insulin reduction, hypoglycemia awareness during physical activity, and blood glucose values prior to physical activity. With this module, a more comprehensive education of patients with specific interest is possible.
Study NCT02702648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-082
Description: Hard gelatin capsules for oral administration
Study NCT02702648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo capsules for oral administration
Study NCT01164722 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clinical observation
Description: Patients undergo observation
Study NCT01164722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: infrared photocoagulation therapy
Description: Anal infrared coagulator ablation
Study NCT04279106 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 0.05% sodium fluoride mouthwash
Description: All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
Study NCT04279106 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: alcohol free essential oils mouthwash
Description: All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
Study NCT04279106 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All subjects were instructed to rinse once a day, in the morning, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
Study NCT00680641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: 40mg of Simvastatin once daily
Study NCT00680641 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40mg of placebo once daily
Study NCT01395524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-118
Description: 12.5 mg oral tablet once daily
Study NCT01395524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-118
Description: 25 mg oral tablet once daily
Study NCT01395524 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet intake once daily
Study NCT06529926 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observational
Description: Only classical physiotherapy application for 4 weeks.
Study NCT06529926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IASTM Technique Application
Description: IASTM application for 2 sessions per week with classical physiotherapy for 4 weeks.
Study NCT01149668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-24781
Description: Subjects enrolled in this study will receive PCI-24781 administered orally at the schedule and dosage from their prior protocol.
Study NCT04384133 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Impulse oscillometry
Description: Impulse oscillometry is a pulmonary function test. During the test, the participant is told to breathe normally.
Study NCT04384133 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Spirometric pulmonary function test
Description: In the spirometric pulmonary function test, the participant is asked to perform respiratory maneuvers such as breathing deeply.
Study NCT04384133 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fractional exhaled nitric oxide (FENO) test
Description: In the FENO test, the participant is asked to perform respiratory maneuvers such as breathing deeply.
Study NCT04384133 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Thorax Computed Tomography
Description: Computed tomography is a radiological examination.
Study NCT04384133 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Chest X Ray
Description: Chest X ray is a radiological examination.
Study NCT04384133 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood eosinophil level
Description: A tube of blood will be drawn from the participant.
Study NCT04384133 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CAT
Description: It consists of 8 questions.
Study NCT00999908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg
Description: Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
Study NCT00999908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 μg
Description: Tiotropium was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
Study NCT04384133 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: mMRC
Description: It is the scale used to measure the severity of shortness of breath.
Study NCT02602756 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Protontherapy
Description: Proton-therapy consists in four consecutive sessions. The experimental arm consists in eight sessions. Irradiation is administered over two weeks, delivering a total dose of 60 Cobalt Gris Equivalent (CGE is the physical Gray dose multiplied by a biological factor of relative efficiency of 1.1 for protons compared to photons).
Study NCT02602756 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Protontherapy
Description: Proton-therapy consists in four consecutive sessions. The experimental arm consists in eight sessions. Irradiation is administered over two weeks, delivering a total dose of 60 Cobalt Gris Equivalent (CGE is the physical Gray dose multiplied by a biological factor of relative efficiency of 1.1 for protons compared to photons).
Study NCT00999908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (matching indacaterol) was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
Study NCT04635800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHU650
Description: MHU650 powder for solution for injection
Study NCT03796520 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EpiPick simplified seizure classification algorithm
Description: EpiPick simplified seizure classification algorithm input:~Grey matter brain lesion Exclusively nocturnal seizures First seizure at age > 20 years Lip smacking or chewing during seizures Staring with impaired awareness, lasting less than 20s without postictal confusion Sudden irregular jerks, in isolation or brief series, if none of the following applies: Are the jerks consistently in the same limb? When resting in bed when falling asleep? Bilateral tonic-clonic seizures within 1h of awakening or immediately preceded by irregular jerks Any of the following is present: Skin turning pale pre-ictally; Loss of consciousness immediately after urination or defecation; Sudden slump with loss of awareness, lasting less than 10 seconds; Seizure lasting longer than 10 minutes, with eyes closed throughout the seizure; Severe pre-ictal headache; Episodes consisting of falls that occur always after change in posture to the upright position, or coughing or feeling pain.
Study NCT02254889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: proton pump inhibitor
Description: ). In the pre-ESD therapeutic group, a standard intravenous dose of PPI was given 2 hours before ESD. In the post-ESD therapeutic group, patients also received intravenous PPI in standard doses, once in the evening after ESD.
Study NCT02254889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: proton pump inhibitor
Description: ). In the pre-ESD therapeutic group, a standard intravenous dose of PPI was given 2 hours before ESD. In the post-ESD therapeutic group, patients also received intravenous PPI in standard doses, once in the evening after ESD.
Study NCT00624390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sepraspray
Study NCT01660958 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MNP
Description: The formulation of the multiple micronutrient powder (MNP) was based on low micronutrient intake, low bioavailability of iron and zinc in the Indian diet, and current World Health Organization (WHO)and Indian recommendations regarding fortification and age-specific nutrient requirements. The MNP formulations were produced by a certified company in India and include: Iron, Vitamin A, Vitamin C, Folic Acid, Zinc, Vitamin B12 Vitamin B2, plus filler (maltodextrin). Placebo included riboflavin and maltodextrin.
Study NCT01660958 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Learning
Description: • Infant will benefit from interventions that are based on responsive parenting, whereby caregivers respond to children's cues, provide opportunities for exploration, and engage in nurturant and reciprocal communication.
Study NCT02809833 — intervention group
Intervention type: DRUG
Intervention: Tocilizumab
Description: Tocilizumab must be selected by the treating physician in advance of the study and will be not provided by the Sponsor. The dose/regimen are at the discretion of the prescriber. However, tocilizumab in the SmPC is specified as 8 milligrams per kilogram (mg/kg) via intravenous (IV) infusion at 4-week intervals.
Study NCT01076257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Constraint-induced Movement Therapy
Description: Home based CIT~1. Restriction of the less affected limb~2. Intensive practice using affected limb~3. Positive experience~4. Functional task (task)
Study NCT01076257 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Modified Constraint-induced Movement Therapy
Description: Home based CIT~1. Restriction of the less affected limb~2. Intensive practice using affected limb~3. Positive experience~4. Functional task (task)
Study NCT00503204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: oral tablet
Study NCT00503204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: oral capsule
Study NCT04583371 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MECHANICAL PULMONARY HYPERINFLUATION
Description: For basal aspiration, the patient will be placed in the supine position with the head elevated at 30º, will be submitted to a single aspiration with a size 12 probe (Mark Med), with a vacuum adjusted to -40cmH2O of pressure, with basic asepsis care being maintained for performing the technique. In the participants of the intervention group, the calculation of the ideal tidal volume of each patient will be performed, after which they will be positioned in the same way as baseline aspiration, in assisted-controlled pressure ventilation, increasing 10 cmH2O in inspiratory pressure and, in ventilatory mode. -controlled by volume, we will increase 50% of the tidal volume for a period of 10 minutes, observing the peak that cannot exceed 40 cmH2O in both ventilation modes, and then three aspirations will be performed for 15 seconds and with an interval of 30 seconds.
Study NCT04264533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC
Description: 12g Vitamin C will be infused in the experimental group twice a day for 7 days by the infusion pump with a speed of 12ml/h.
Study NCT03060122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIN
Description: The InterX device will be applied by a trained therapist along the course of the dermatomes in the affected area, paying special attention to the location of major cutaneous nerves ensuring optimal treatment points are identified and treated within the neurologically related area.
Study NCT03060122 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIN
Description: The InterX device will be applied by a trained therapist along the course of the dermatomes in the affected area, paying special attention to the location of major cutaneous nerves ensuring optimal treatment points are identified and treated within the neurologically related area.
Study NCT03060122 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham CES
Description: The sham CES is identical to the regular device but ear clips will emit a dose at 100 mA, a sub-sensory level.
Study NCT03060122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CES
Description: Cranial Electrical Stimulation (CES) Alpha-Stim is a noninvasive medical treatment device that delivers a microcurrent (100 to 500 microamperes) via ear clip electrodes connected to a handheld device.
Study NCT04264533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Water for Injection
Description: 50ml sterile water for injection will be infused in the placebo comparator group twice a day for 7 days by the infusion pump with a speed of 12ml/h.
Study NCT01197287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAK423A
Study NCT02889367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir 100 mg
Description: Participants will receive odalasvir 2\*50 mg tablet, orally once on Day 1.
Study NCT02889367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive odalasvir matching placebo, tablet, orally once on Day 1.
Study NCT02889367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir 500 mg
Description: Participants will receive odalasvir 10\*50 mg tablet, orally once on Day 1.
Study NCT02889367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir (Up to maximum 1000 mg)
Description: Participants will receive odalasvir to be decided up to maximum of 20\*50 mg tablet, orally once on Day 1.
Study NCT00358540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag
Description: Dosing of sarcoma subjects with eltrombopag after treatment with Adriamycin and Ifosfamide.
Study NCT04679415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hzVSF-v13
Description: Dosage form: hzVSF-v13 40 mg/mL in a 5 mL vial Frequency: Dose at Day 1, 3, 7
Study NCT04679415 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Normal saline solution)
Description: Dosage form: 0.9% NaCl Solution Frequency: Dose at Day 1, 3, 7
Study NCT03500445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab (16 mg/kg) will be administered as an IV infusion:~* Cycle 1-2: 16 mg/kg weekly~* Cycles 3-8: 16 mg/kg IV infusion every 2 weeks~* Cycles 9-24: 16 mg/kg IV infusion Day 1
Study NCT03500445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be given as an IV infusion over 30 minutes:~* Cycle 1: 20 mg/m2 Days 1, 2; 36 mg/m2 Days 8, 9, 15, 16. Alternatively, intermediate dose escalation (to 27mg/m2 on days 8, 9 of cycle 1) will be allowed at the treating physician's discretion.~* Cycle 2-9: 36 mg/m2 (or best tolerated dose) Days 1, 2, 8, 9, 15 and 16~* Cycles 9-24: 36 mg/m2 (or best tolerated dose) Days 1, 2, 15 and 16
Study NCT03500445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be taken orally as follows:~• Cycles 1-24: 25 mg (or best tolerated dose) PO Days 1-21
Study NCT03500445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered prior to carfilzomib (on days that they coincide), as follows:~* Cycles 1-9: 40 mg PO (subjects ≤ 75 years) or 20 mg PO (subjects ≥ 75 years) per week~* Cycles 9-24: 20 mg PO per week~During weeks when daratumumab is given: 40 mg dexamethasone weekly, 20 mg prior to daratumumab infusion and 20 mg PO the day after~During weeks with no daratumumab, single dose of 20 mg on day 1
Study NCT04856514 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEERS
Description: 16 week telehealth intervention; parallel teen and parent/caregiver groups; 90 minutes each week.
Study NCT04241614 — intervention group
Intervention type: OTHER
Intervention: No interventions
Description: No interventions
Study NCT03285243 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Monochromatic blue light
Description: Exposure to monochromatic light for the first 30 minutes in the recovery period after anesthesia to assess incidence of emergence delirium as noted by the PAED scale
Study NCT03285243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monochromatic blue light
Description: Exposure to monochromatic light for the first 30 minutes in the recovery period after anesthesia to assess incidence of emergence delirium as noted by the PAED scale
Study NCT04467580 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: abdominal [18F]FDG PET/CT
Description: Patients will have within a maximum period of 15 days before the surgery (resection of intestinal stenosis), records by MRI and by digital PET/CT with low injected activity of \[18F\]FDG, focused on the abdomen, the MRI will be performed maximum 30 days before the intervention (if available and performed according to the procedure for the study, it will not be repeated for the study).
Study NCT00131846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiazide diuretics
Description: Any dosage, frequency, and duration
Study NCT00131846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No diuretics
Description: Any antihypertensive regimen other than diuretics
Study NCT05536661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preservative free hyaluronic acid artificial tear
Description: Ocular lubricant
Study NCT02885571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SomnoDent Flex with DentiTrac
Study NCT02885571 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SomnoDent Flex with DentiTrac
Study NCT02282683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Prednisone (10 to 20 mg/day, orally) combined with maximum tolerated guideline-directed medical therapy for at least 12 months
Study NCT02486757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: micronized progesterone
Study NCT02486757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transdermal estradiol
Study NCT04314960 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation device (NESS L300Plus, Bioness, Valencia, CA)
Description: Functional electrical stimulation (FES) is the application of high-intensity intermittent electrical stimuli to generate muscle contractions that may bypass spinal and supraspinal inhibition, and which is coupled with a functional task such as gait. Gait training will be conducted on a treadmill.
Study NCT01510678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase Fruits and Vegetables
Description: Children will be encouraged to consume 1 cup/day and 1.5 cups/day of whole fruit, and 1.5 cups/day and 2 cups/day of vegetables for children aged 6 to 8 years and 9 to 12 years, respectively. Children will gradually work towards these goals. Parents will also work towards F\&V goals, with 2 cups/day of whole fruit and 2.5 cups/day of vegetables. Both parent and child will self-monitor these behaviors. As one barrier to consuming F\&Vs is perceived cost of these foods, information regarding lower-cost options for F\&Vs will be included in the manual.
Study NCT01510678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decrease Snack Foods
Description: This condition will reduce intake of SFs (i.e., candy, cookies, cakes, ice cream, chips, nuts) to \< 3 servings/week (for children aged 6 to 12 years, the solid fats and added sugar energy limit is 840 kcals/week and the DECREASE goal will help with meeting this limit). Children and parents will gradually work towards meeting these goals and self-monitor these behaviors.
Study NCT01731938 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibrin Sealant (FS) Grifols
Description: Fibrin Sealant (FS) Grifols: The maximum total volume of FS Grifols allowed to be applied at the target bleeding site by dripping or spraying was approximately 12 mL (equivalent to the full content of 2 FS Grifols kits).
Study NCT01731938 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgicel®
Description: Up to four Surgicel® sheets applied to the target bleeding site according to Package Insert instructions and the surgeon's usual clinical practice.
Study NCT01510678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase Fruits and Vegetables and Decrease Snack Foods
Description: Will combine the goals of the increase and decrease conditions.